Is it safe to prescribe Lunesta (eszopiclone) for insomnia in a patient with a documented history of seizures?

Lunesta and History of Seizures

Lunesta (eszopiclone) can be used cautiously in patients with a history of seizures, but requires careful consideration of seizure control status and concurrent anticonvulsant use, as it may produce additive CNS-depressant effects when combined with anticonvulsants.

Key Safety Considerations from FDA Labeling

The FDA label for Lunesta explicitly states that dose adjustment may be necessary when eszopiclone is administered with other CNS-depressant agents, including anticonvulsants, because of potentially additive effects 1. This is critical because:

• Most patients with seizure history are on anticonvulsant medications
• The combination increases CNS depression risk
• Eszopiclone itself has CNS-depressant properties that could theoretically lower seizure threshold

Recent Pharmacovigilance Data

A 2025 comprehensive analysis of adverse event reports from 1967-2023 provides crucial safety data. Z-drugs (including eszopiclone) showed a significant association with seizure reports (ROR 1.58,95% CI 1.49-1.69) 2. However, this association was notably lower than benzodiazepines (ROR 2.56) and antidepressants (ROR 2.52) 2.

This suggests eszopiclone carries seizure risk, but less than alternative sedative-hypnotics commonly used for insomnia.

Clinical Decision Algorithm

For patients with well-controlled seizures:

• Eszopiclone can be prescribed starting at the lowest effective dose (1 mg for elderly, 2 mg for non-elderly)
• Coordinate with the patient's neurologist regarding anticonvulsant interactions
• Reduce eszopiclone dose by 50% if on strong CYP3A4 inhibitors
• Monitor for breakthrough seizures in the first 2-4 weeks

For patients with poorly controlled or recent seizures:

• Consider orexin receptor antagonists (daridorexant, lemborexant, suvorexant) as first-line pharmacotherapy instead, as these showed no significant seizure signal (ROR 0.81,95% CI 0.61-1.07) 2
• If eszopiclone is necessary, use only after seizure stabilization and with explicit neurologist approval

For all patients with seizure history:

• Prioritize cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment per ACP guidelines 3
• Avoid alcohol completely, as the FDA warns that alcohol combined with eszopiclone increases risk of complex behaviors and CNS depression 1
• Use lowest effective dose and avoid exceeding maximum recommended doses

Important Caveats

The FDA label does not list seizure disorder as an absolute contraindication, but emphasizes that eszopiclone should only be initiated after careful evaluation to rule out underlying physical/psychiatric disorders 1. The failure of insomnia to improve after 7-10 days warrants re-evaluation 1.

Common pitfall to avoid: Do not assume all hypnotics carry equal seizure risk. The pharmacovigilance data clearly shows orexin receptor antagonists have superior safety profiles in seizure-prone patients compared to Z-drugs, benzodiazepines, or antidepressants 2.

Practical Prescribing

If prescribing eszopiclone to a patient with seizure history:

• Start with 1 mg (even in non-elderly adults) to assess tolerance
• Take immediately before bed only
• Document discussion of increased seizure risk with concurrent anticonvulsants
• Schedule follow-up within 2 weeks to assess efficacy and safety
• Warn about next-day impairment, especially with anticonvulsant co-administration 1

The most prudent approach balances the 2016 ACP guideline recommendation for CBT-I first 3 with the 2025 pharmacovigilance evidence showing eszopiclone has measurable but moderate seizure risk 2, making it a reasonable second-line option when non-pharmacologic approaches fail and orexin antagonists are unavailable or unsuitable.